22 completed, 3 unknown, 2 withdrawn, 1 terminated. 14 Phase 2, 7 Phase 4, 6 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 11, Withdrawn 2, Terminated 1 |
| Phase 4 | 7 | Completed 4, Unknown 3 |
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow Heron Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pediatric Postoperative Analgesia Herniorrhaphy Study HTX-011, Bupivacaine HCl, Luer Lock Applicator - Analgesia | Phase 2 | Withdrawn | Heron Therapeutics | 2023-07-01 | 2026-05-12 | |
| ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy ZYNRELEF 200Mg-6Mg Extended-Release Solution - Post Operative Pain, Acute, Bariatric Surgery Candidate | Phase 4 | Unknown | Dr. Yannis Raftopoulos | 120 | 2023-05-09 | 2023-05-18 |
| Safety Study of Repeat Doses of SUSTOL in Adults SUSTOL - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 4 | Unknown | Heron Therapeutics | 300 | 2022-07-06 | 2023-07-28 |
| HTX-011 in Spinal Surgery Bupivacaine HCI without epinephrine, HTX-011, Luer Lock Applicator - Post-Operative Pain, Lumbar Laminectomy | Phase 2 | Completed | Heron Therapeutics | 32 | 2022-04-07 | 2023-06-12 |
| A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. HTX-011, Bupivacaine Hydrochloride, Ibuprofen - Postoperative Pain, Total Shoulder Arthroplasty | Phase 4 | Completed | Heron Therapeutics | 30 | 2021-10-20 | 2023-10-31 |
| A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. Bupivacaine Hydrochloride, HTX-011, Luer lock applicator - Analgesia | Phase 4 | Unknown | Heron Therapeutics | 90 | 2021-10-12 | 2023-10-26 |
| A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE HTX-011, Bupivacaine Hydrochloride, Ibuprofen - Analgesia | Phase 4 | Completed | Heron Therapeutics | 30 | 2021-10-12 | 2023-10-31 |
| Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting GRANISETRON EXTENDED RELEASE INJECTION (GERSC) - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2020-08-15 | 2020-09-30 | |
| Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) Aprepitant injectable emulsion, Saline Placebo - COVID-19 | Phase 2 | Terminated | Heron Therapeutics | 27 | 2020-07-20 | 2026-03-02 |
| Dose-Escalation Study of HTX-034 Following Bunionectomy HTX-034 low dose, HTX-034 high dose, Luer lock applicator - Bunions, Postoperative Pain | Phase 1 / Phase 2 | Completed | Heron Therapeutics | 78 | 2020-05-08 | 2026-06-09 |
| HTX-011 Administration Study in Planned Caesarean Section Procedure HTX-011, Luer Lock Applicator, Ibuprofen - Analgesia | Phase 2 | Completed | Heron Therapeutics | 25 | 2019-06-24 | 2022-03-14 |
| Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen HTX-011, Ibuprofen, Acetaminophen - Analgesia | Phase 3 | Completed | Heron Therapeutics | 116 | 2019-06-05 | 2026-03-02 |
| Study of Post-Herniorrhaphy Non-opioid MMA Regimens HTX-011, Luer lock applicator, Ibuprofen - Analgesia | Phase 3 | Completed | Heron Therapeutics | 209 | 2019-04-04 | 2026-06-04 |
| Phase 2 Bunionectomy HTX-011 Administration Study HTX-011, Luer Lock applicator, Vial access device - Postoperative Pain | Phase 2 | Completed | Heron Therapeutics | 78 | 2018-10-24 | 2026-03-02 |
| Phase 2 Herniorrhaphy Study for Opioid Elimination HTX-011, Luer lock applicator, Vial access device - Postoperative Pain | Phase 2 | Completed | Heron Therapeutics | 63 | 2018-10-01 | 2026-03-02 |
| Bupivacaine HCl PK and Safety in Augmentation Mammoplasty Bupivacaine HCl - Analgesia | Phase 4 | Completed | Heron Therapeutics | 30 | 2018-09-19 | 2018-12-07 |
| Extended Delivery of Bupivacaine Study in Herniorrhaphy Bupivacaine liposome injectable suspension, Bupivacaine HCl without epinephrine via continuous infusion - Analgesia | Phase 4 | Completed | Heron Therapeutics | 32 | 2018-07-02 | 2019-09-26 |
| Bunionectomy Study for Postoperative Analgesia (EPOCH 1) HTX-011, Saline Placebo, Bupivacaine HCl - Postoperative Pain | Phase 3 | Completed | Heron Therapeutics | 412 | 2017-10-24 | 2026-03-02 |
| Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) HTX-011, Bupivacaine HCl, Saline placebo - Postoperative Pain | Phase 3 | Completed | Heron Therapeutics | 418 | 2017-07-31 | 2026-03-02 |
| Phase 2B Upper Extremity Nerve Block Study HTX-011, Bupivacaine HCl without epinephrine, Saline Placebo - Postoperative Pain | Phase 2 | Completed | Heron Therapeutics | 243 | 2017-01-14 | 2026-03-02 |
Showing 20 of 28. Sign in to see all of them.
Pain, Postoperative (20) · Agnosia (11) · Hernia, Inguinal (5) · Bunion (4) · Hernia (4) · Vomiting (4) · COVID-19 (1) · Coronavirus Infections (1) · Nausea (1)
Bupivacaine (13) · Acetaminophen (7) · Ibuprofen (7) · Granisetron (3) · bupivacaine-meloxicam drug combination (3) · Dexamethasone (2) · Epinephrine (2) · Aprepitant (1) · Celecoxib (1) · Injections, Subcutaneous (1) · KPNA1 protein, human (1) · Ketorolac (1) · Ondansetron (1) · Palonosetron (1) · Ropivacaine (1)
United States (27) · Belgium (1)
Albert Dietz, MD, PhD (1) · John Barr, PhD (1) · Mark Gelder, MD (1) · Neil Singla, MD (1) · Rudolph M Navari, MD (1) · Yannis Raftopoulos, MD (1)
PMID 34284613, PMID 26289588, PMID 26921245, PMID 26997579, PMID 31113830, PMID 31843865, PMID 32561266, PMID 34318438